Pfizer Inc. PFE announced today the completion of pneumonia case
accrual in the Community-Acquired Pneumonia Immunization Trial in Adults
(CAPiTA) 65 years of age and older. CAPiTA, the largest trial of its
kind, was designed to evaluate whether Prevenar 13* (Pneumococcal
polysaccharide conjugate vaccine [13-valent, adsorbed]) is effective in
preventing community-acquired pneumonia (CAP) caused by the 13
pneumococcal serotypes included in the vaccine.1 It is an
event-driven clinical study, meaning that a pre-specified number of
community-acquired, vaccine-type pneumococcal pneumonia cases have to
occur among study participants before the results can be determined.
As specified in the study protocol, all remaining suspected cases
currently in review will be fully processed to allow the database to
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in